Effect of denosumab on bone turnover markers in postmenopausal osteoporosis: Initial response and subsequent release from suppression

被引：0
|
作者：
Eastell, R. [1 ]
Austin, M. [2 ]
Martin, J. San [3 ]
McClung, M. R. [4 ]
Christiansen, C. [5 ]
Libanati, C. [3 ]
Siris, E. S. [6 ]
Cummings, S. R. [7 ]
机构：
[1] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England
[2] Amgen Inc, Clin Biostat, Thousand Oaks, CA 91320 USA
[3] Amgen Inc, Dept Med, Thousand Oaks, CA 91320 USA
[4] Univ Oregon, Oregon Osteoporosis Ctr, Portland, OR USA
[5] Ctr Clin & Basic Res, Dept Med, Ballerup, Denmark
[6] Columbia Univ, Med Ctr, Dept Med, New York, NY USA
[7] UCSF, Clin Trial Coordinating Ctr, San Francisco, CA USA
来源：
BONE | 2009年 / 44卷 / 02期
关键词：
D O I：
10.1016/j.bone.2009.03.105
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S242 / S243
页数：2
相关论文
共 50 条
  • [41] Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis
    Aki, S
    Gulbaba, RG
    Eskiyurt, N
    JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION, 2003, 17 (01) : 27 - 31
  • [42] BONE MARKERS IN POSTMENOPAUSAL WOMEN: EVALUATION OF OSTEOPOROSIS RISK INDEX IN WOMEN TREATED WITH DENOSUMAB
    Kocevska, A. K.
    Todorova, B. J. T. Jovanoska
    Nakov, A. N.
    Kocevska, B. K.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S321 - S321
  • [43] High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
    Ishikawa, Koji
    Nagai, Takashi
    Sakamoto, Keizo
    Ohara, Kenji
    Eguro, Takeshi
    Ito, Hiroshi
    Toyoshima, Yoichi
    Kokaze, Akatsuki
    Toyone, Tomoaki
    Inagaki, Katsunori
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1831 - 1840
  • [44] In postmenopausal osteoporosis bone histomorphometry, but not biochemical bone turnover markers correlate with bone mineral density
    Retallack, RW
    Gutteridge, DH
    Glendenning, P
    Holzherr, M
    Will, RK
    Watson, I
    Matz, L
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) : 822 - 822
  • [45] Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis
    P. Szulc
    P. D. Delmas
    Osteoporosis International, 2008, 19 : 1683 - 1704
  • [46] EFFECTS OF DIMETHIL PAMIDRONATE TREATMENT ON BIOCHEMICAL MARKERS OF BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS
    ZANCHETTA, JR
    BOGADO, CE
    JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 : S196 - S196
  • [47] Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis
    Szulc, P.
    Delmas, P. D.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (12) : 1683 - 1704
  • [48] Bone Turnover Markers for Osteoporosis Status Assessment at Baseline in Postmenopausal Pakistani Females
    Naeem, Syed Talha
    Hussain, Riffat
    Raheem, Ahmed
    Siddiqui, Imran
    Ghani, Farooq
    Khan, Aysha Habib
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2016, 26 (05): : 408 - 412
  • [49] Are Bone Turnover Markers Related with Fracture Risk in Initial Diagnose Postmenopausal Osteoporosis? A Cross-Sectional Clinical Study
    Yalbuzdag, Seniz Akcay
    Sarifakioglu, Banu
    Sengul, Ilker
    Cetin, Nuri
    TURK OSTEOPOROZ DERGISI-TURKISH JOURNAL OF OSTEOPOROSIS, 2015, 21 (02): : 58 - 62
  • [50] Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis
    Mengu Sarioglu
    Cigdem Tuzun
    Zeliha Unlu
    Canan Tikiz
    Fatma Taneli
    B. Sami. Uyanik
    Rheumatology International, 2006, 26 : 195 - 200
12345